- The total export value of Remsima®
- In October 2016, Remsima®'s total export value reached EUR 780 million (the Korea International Trade Association).
- Number of overseas subsidiaries
- The number of countries with Celltrion Healthcare’s overseas subsidiaries(2019).
- Number of global partners
- Global partners in charge of the biologics’ distribution along with Celltrion Healthcare(2019).
- Remsima®'s market share
bypassing that of the orginator
- Remsima® is the first mAb biosimilar to bypass the originator's market share in Europe (2017).
- Sales market
- The number of countries where Celltrion Healthcare’s core biosimilars are available for purchase(and officially approved, 2019).
- The annual value of Remsima®
prescribed in the world
- For the first time as a Korean medication,
the annual value of Remsima® prescribed across the world reached EUR 770million (2018).